- Home
- TII vs SABS Comparison
TII vs SABS Comparison
Compare TII & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TII | SABS |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.1M | 181.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TII | SABS |
|---|---|---|
| Price | $2.27 | $3.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 74.4K | ★ 287.8K |
| Earning Date | 03-20-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $75,461,000.00 | $114,698.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.96 | ★ N/A |
| Revenue Growth | ★ 54.36 | N/A |
| 52 Week Low | $0.26 | $1.00 |
| 52 Week High | $3.39 | $6.60 |
Technical Indicators
Market Signals| Indicator | TII | SABS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.03 |
| Support Level | N/A | $3.54 |
| Resistance Level | N/A | $4.04 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 71.91 |
Price Performance
Historical ComparisonAbout TII Titan Mining Corporation
Titan Mining Corp is a Canadian natural resources company. It is engaged in the acquisition, exploration, and development of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States. The Company operates one reportable segment, mineral production and exploration in the United States.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.